The FDA Group's Nick Capman sits down with Stephen Poor, a physician-scientist with over 20 years of experience in the industry, mainly with Novartis — currently serving as Novartis's Global Program Clinical Head (Executive Director).
They delve into the psychological and professional impacts of organizational changes, particularly focusing on identity and adaptation during times of transition, such as layoffs or department closures.
Discussion points include:
» Stephen's transition due to organizational shutdown and his journey through change.
» Stephen's experiences and thought processes from realizing Novartis's exit from ophthalmology to starting a new job, focusing on identity in times of change.
» The importance of maintaining a positive outlook, using visualization techniques, and combating self-limiting beliefs during periods of professional uncertainty.
» Predictions for 2024 and 2025.
» Nick's upcoming book, "The Passionate Workforce," is based on 15 pillars aimed at creating a motivated and high-performing organizational culture.
» Insights into managing layoffs thoughtfully, ensuring those who leave feel respected and valued.The FDA Group's strategic plans include potential acquisitions to leverage anticipated economic growth.
» The need for positive thinking, proactive planning, and readiness to capitalize on upcoming opportunities in the life sciences industry.
Stephen Poor is the Global Program Clinical Head at Novartis, bringing over 20 years of experience in ophthalmology biotech-pharma and a strong medical background to his role. He is at the forefront of developing innovative therapies for retinal diseases, focusing on age-related macular degeneration (AMD) and geographic atrophy (GA), the leading causes of blindness in the elderly. Poor leads the clinical team for PPY998 (GT005), a Phase 2b subretinal complement factor I gene therapy for GA, a significant acquisition from Gyroscope in 2021. His responsibilities extend beyond PPY998 to overseeing undisclosed gene therapy programs and novel drug delivery devices.
In his leadership role, Stephen is pivotal in bridging the gap between Novartis's research, development, and commercial sectors through strategic collaboration and advisory duties. He plays a key role in external strategy, asset and technology review to enhance the department's portfolio, and coordination of scientific support for the portfolio.
A Journey into Life Sciences Investment: Strategies, Challenges, and Opportunities with Sal Buscemi
Navigating Risk Management in Medical Devices with Brian Dense
The DEA, FDA & Controlled Substances: An Insider's Perspective with Former DEA Agent Dennis Wichern
A Deep Dive into Medical Device Regulatory Strategy with Regulatory Attorney Christine P. Bump
Lessons from a Medtech Entrepreneur: Ram Konduru on Fostering Teamwork and Personal Growth in Leadership
Unlocking Effective Leadership: A Conversation with MetaComet Systems President, David Marlin
Leadership, Management, and Enhancing Quality of Life: A Conversation with Dan Barker, CEO of Wikimotive
Navigating the 510(k) Process: A Q&A with Regulatory Consultant, Trey Thorsen, MS, RAC
The Future of Life Science Talent Acquisition: Securing In-Demand Skills in a Competitive Market
FDA Revives Its Proposed Quality Metrics Program for Pharma
Inspection Alternatives Are Driving More FDA Enforcement Actions: What It Means for Industry
FDA's Domestic Biopharma Inspections Return to Normal
Quality Management Review: Benchmarking Quantitatively!
Addressing FDA's Inspection Backlog with Mary Denigan-Macauley, GAO's Director of Health Care
FDA's Fraudulent Products Task Force and Operation Quack Hack Battle COVID Vaccine Scams
What to Expect for the FDA's Regulation of Medical Devices & Digital Health Under the Biden Administration
Clinical Outsourcing & Insourcing: Selecting the Right Model or Mix
What RA/QA/Clinical Leaders Should Expect From the FDA in 2021
Inside FDA Pre-Approval Inspections with Former FDA Investigator, Christopher Smith
A Look at FDA's Pandemic Inspections Q&A Guidance
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Ground Truths